WOCKPHARMA Stock Overview
Wockhardt Limited, a pharmaceutical and biotechnology company, manufactures and markets active pharmaceutical ingredients, formulations, bio-similars, and vaccines in India, the United States, Europe, and internationally.
Price History & Performance
|Historical stock prices|
|Current Share Price||₹212.65|
|52 Week High||₹592.00|
|52 Week Low||₹210.05|
|1 Month Change||-20.59%|
|3 Month Change||-22.65%|
|1 Year Change||-59.78%|
|3 Year Change||-42.57%|
|5 Year Change||-64.45%|
|Change since IPO||-21.19%|
Recent News & Updates
Is Wockhardt (NSE:WOCKPHARMA) Using Too Much Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
|WOCKPHARMA||IN Pharmaceuticals||IN Market|
Return vs Industry: WOCKPHARMA underperformed the Indian Pharmaceuticals industry which returned -15.9% over the past year.
Return vs Market: WOCKPHARMA underperformed the Indian Market which returned -0% over the past year.
|WOCKPHARMA Average Weekly Movement||7.3%|
|Pharmaceuticals Industry Average Movement||6.9%|
|Market Average Movement||7.0%|
|10% most volatile stocks in IN Market||9.9%|
|10% least volatile stocks in IN Market||4.5%|
Stable Share Price: WOCKPHARMA is not significantly more volatile than the rest of Indian stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: WOCKPHARMA's weekly volatility (7%) has been stable over the past year.
About the Company
Wockhardt Limited, a pharmaceutical and biotechnology company, manufactures and markets active pharmaceutical ingredients, formulations, bio-similars, and vaccines in India, the United States, Europe, and internationally. The company offers generic products comprising injectables, such as cephalosporins and non-cephalosporins; molecules; and value-added generics. Its biopharmaceutical products include Glaritus, an insulin analog; Wosulin, an r-DNA insulin; Wepox, a recombinant erythropoietin that is used in the treatment of anemia caused by cancer and chronic renal failure; and Biovac-B, a hepatitis B vaccine.
Wockhardt Fundamentals Summary
|WOCKPHARMA fundamental statistics|
Is WOCKPHARMA overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|WOCKPHARMA income statement (TTM)|
|Cost of Revenue||₹12.67b|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-16.94|
|Net Profit Margin||-7.55%|
How did WOCKPHARMA perform over the long term?See historical performance and comparison
Is WOCKPHARMA undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for WOCKPHARMA?
Other financial metrics that can be useful for relative valuation.
|What is WOCKPHARMA's n/a Ratio?|
Price to Sales Ratio vs Peers
How does WOCKPHARMA's PS Ratio compare to its peers?
|WOCKPHARMA PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
STAR Strides Pharma Science
530549 Shilpa Medicare
SPARC Sun Pharma Advanced Research
Price-To-Sales vs Peers: WOCKPHARMA is good value based on its Price-To-Sales Ratio (0.9x) compared to the peer average (11.8x).
Price to Earnings Ratio vs Industry
How does WOCKPHARMA's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?
Price-To-Sales vs Industry: WOCKPHARMA is good value based on its Price-To-Sales Ratio (0.9x) compared to the Indian Pharmaceuticals industry average (1.7x)
Price to Sales Ratio vs Fair Ratio
What is WOCKPHARMA's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||0.9x|
|Fair PS Ratio||n/a|
Price-To-Sales vs Fair Ratio: Insufficient data to calculate WOCKPHARMA's Price-To-Sales Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of WOCKPHARMA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: WOCKPHARMA (₹212.65) is trading above our estimate of fair value (₹145.01)
Significantly Below Fair Value: WOCKPHARMA is trading above our estimate of fair value.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate WOCKPHARMA's PEG Ratio to determine if it is good value.
Discover undervalued companies
How is Wockhardt forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Wockhardt has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Discover growth companies
How has Wockhardt performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: WOCKPHARMA is currently unprofitable.
Growing Profit Margin: WOCKPHARMA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: WOCKPHARMA is unprofitable, but has reduced losses over the past 5 years at a rate of 28.2% per year.
Accelerating Growth: Unable to compare WOCKPHARMA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: WOCKPHARMA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (9%).
Return on Equity
High ROE: WOCKPHARMA has a negative Return on Equity (-6.64%), as it is currently unprofitable.
Discover strong past performing companies
How is Wockhardt's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: WOCKPHARMA's short term assets (₹25.9B) do not cover its short term liabilities (₹32.1B).
Long Term Liabilities: WOCKPHARMA's short term assets (₹25.9B) exceed its long term liabilities (₹8.3B).
Debt to Equity History and Analysis
Debt Level: WOCKPHARMA's net debt to equity ratio (34.4%) is considered satisfactory.
Reducing Debt: WOCKPHARMA's debt to equity ratio has reduced from 111.8% to 44.3% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable WOCKPHARMA has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: WOCKPHARMA is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 32.9% per year.
Discover healthy companies
What is Wockhardt current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate WOCKPHARMA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate WOCKPHARMA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if WOCKPHARMA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if WOCKPHARMA's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: WOCKPHARMA is not paying a notable dividend for the Indian market.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as WOCKPHARMA has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Murtaza Khorakiwala (48 yo)
Dr. Murtaza Habil Khorakiwala serves as the Managing Director of Wockhardt Ltd. since April 2009 and has been its Executive Director since March 31, 2009. Dr. Khorakiwala serves as a Director of Khorakiwal...
CEO Compensation Analysis
Compensation vs Market: Murtaza's total compensation ($USD306.01K) is about average for companies of similar size in the Indian market ($USD259.68K).
Compensation vs Earnings: Murtaza's compensation has been consistent with company performance over the past year.
Experienced Management: WOCKPHARMA's management team is seasoned and experienced (10.8 years average tenure).
Experienced Board: WOCKPHARMA's board of directors are considered experienced (9.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 30%.
Wockhardt Limited's employee growth, exchange listings and data sources
- Name: Wockhardt Limited
- Ticker: WOCKPHARMA
- Exchange: NSEI
- Founded: 1999
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: ₹30.633b
- Shares outstanding: 144.05m
- Website: https://www.wockhardt.com
Number of Employees
- Wockhardt Limited
- Wockhardt Towers
- Bandra Kurla Complex
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/06/28 00:00|
|End of Day Share Price||2022/06/28 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.